Events
Frost & Sullivan has presented INTEGRA Biosciences with the ‘2018 Global Laboratory Pipetting Company of the Year’ award, recognizing its products as innovative, revolutionary and able to fulfil the needs of customers.
MC Services AG is, once again, sponsoring the “Deutsches Eigenkapitalforum” (German Equity Forum) and will host the event’s press lounge. The Forum will be held in Frankfurt am Main, November 26-28, 2018.
BioArctic AB will present at Jefferies 2018 London Healthcare Conference on November 15, at 4.40 p.m. local time (GMT).
Shifa Biomedical Corporation today announced exciting preclinical data involving the company’s pre-clinical candidate, P-21, which interferes with the interaction between PCSK9 and the LDL receptor (LDLR).
The Biotechnology Industry Organization (BIO) published the fifth edition of the Building the Bioeconomy report recently. The report studied 28 different indicators and provided analysis and insight into the biotech environment for 33 countries. The goal of the report is to determine how successful biotechnology sectors can be created and sustained.
Esperion today announced that the final Phase 3 results from Study 3 (1002-046, also known as CLEAR Serenity) were presented at the American Heart Association (AHA) Scientific Sessions in Chicago.
Initial data from AMBER trial of TSR-022 (anti-TIM-3) in combination with TSR-042 (anti-PD-1) demonstrated clinical activity in patients who have progressed following anti-PD-1 treatment
Results to be presented at the AASLD congress 2018, 9-13 November
Medtronic plc announced today that it will report financial results for the second quarter of fiscal year 2019 on Tuesday, November 20, 2018. A news release will be issued at approximately 5:45 a.m. Central Standard Time (CST) and will be available at http://newsroom.medtronic.com.
During the annual congress of the French Society of Pathology which is held held from 5th to 8th November 2018 in Paris, AP-HP, Greater Paris University Hospitals and TRIBVN Healthcare are pleased to announce a 5-year strategic partnership to develop and operate a National Telepathology Platform.
PRESS RELEASES